Search research articles
Contact Us
Filters
Showing results (81-90 of 290) with videos related to
Page
of 29
Sort By:
Gastroenterology
|
September 19, 2015
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
Joana Torres, Ray K Boyapati, Nicholas A Kennedy, et al.
Clinics and Research in Hepatology and Gastroenterology
|
January 28, 2026
QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study
Alice Dongier, Edouard Louis, Jean-Philippe Loly, et al.
The Lancet. Healthy Longevity
|
September 13, 2022
Is it time to include older adults in inflammatory bowel disease trials? A call for action
Sophie Vieujean, Bénédicte Caron, Vipul Jairath, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
September 14, 2011
Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis
David G Binion, Edouard Louis, Bas Oldenburg, et al.
European Journal of Gastroenterology & Hepatology
|
April 16, 2002
Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources
Edouard Louis, Danny DeLooze, Pierre Deprez, et al.
Expert Opinion on Pharmacotherapy
|
July 4, 2023
Stemming the tide with ileocecal Crohn's disease: when is pharmacotherapy enough?
Sophie Vieujean, Paulo Gustavo Kotze, Patrick Netter, et al.
Inflammatory Bowel Diseases
|
April 8, 2011
Natalizumab to kill two birds with one stone: a case of celiac disease and multiple sclerosis
Rémy Phan-Ba, Nadine Lambinet, Edouard Louis, et al.
Revue Medicale De Liege
|
February 14, 2025
[MR Imaging of ano-perineal fistulas]
Paul Meunier, Catherine Reenaers, Catherine Van Kemseke, et al.
Advances in Therapy
|
March 23, 2021
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease
Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus, et al.
Inflammatory Bowel Diseases
|
April 12, 2023
In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab
Jean-Philippe Loly, Sophie Vieujean, Catherine Reenaers, et al.
Page
of 29
Search research articles
Search
Showing results (81-90 of 290) with videos related to
Sort By:
Page
of 29
Gastroenterology
|
September 19, 2015
Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
Joana Torres, Ray K Boyapati, Nicholas A Kennedy, et al.
Clinics and Research in Hepatology and Gastroenterology
|
January 28, 2026
QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study
Alice Dongier, Edouard Louis, Jean-Philippe Loly, et al.
The Lancet. Healthy Longevity
|
September 13, 2022
Is it time to include older adults in inflammatory bowel disease trials? A call for action
Sophie Vieujean, Bénédicte Caron, Vipul Jairath, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
September 14, 2011
Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis
David G Binion, Edouard Louis, Bas Oldenburg, et al.
European Journal of Gastroenterology & Hepatology
|
April 16, 2002
Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources
Edouard Louis, Danny DeLooze, Pierre Deprez, et al.
Expert Opinion on Pharmacotherapy
|
July 4, 2023
Stemming the tide with ileocecal Crohn's disease: when is pharmacotherapy enough?
Sophie Vieujean, Paulo Gustavo Kotze, Patrick Netter, et al.
Inflammatory Bowel Diseases
|
April 8, 2011
Natalizumab to kill two birds with one stone: a case of celiac disease and multiple sclerosis
Rémy Phan-Ba, Nadine Lambinet, Edouard Louis, et al.
Revue Medicale De Liege
|
February 14, 2025
[MR Imaging of ano-perineal fistulas]
Paul Meunier, Catherine Reenaers, Catherine Van Kemseke, et al.
Advances in Therapy
|
March 23, 2021
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease
Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus, et al.
Inflammatory Bowel Diseases
|
April 12, 2023
In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab
Jean-Philippe Loly, Sophie Vieujean, Catherine Reenaers, et al.
Page
of 29